2-years outcomes of the treat-to-target strategy in early psoriatic arthritis
| Autor: | E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, P. O. Tremaskina, S. I. Glukhova, E. L. Nasonov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Научно-практическая ревматология, Vol 60, Iss 5, Pp 580-586 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1995-4484 1995-4492 |
| DOI: | 10.47360/1995-4484-2022-580-586 |
| Popis: | Aim – to study 2 years outcomes of the treat-to-target (T2T) strategy in early psoriatic arthritis (ePsA) patients. Material and methods. 68 (33 male/35 female) ePsA patients according to CASPAR criteria (mean age – 37.3±10.8 years; PsA duration – 11.0±9.8 months) were included and were observed till 2 years follow-up. At baseline and every 3 months all patients underwent standard clinical examinations. All patients was given mono-therapy with Methotrexate (MTX) s/c or in combination with biological (b) DMARDs. The number of pts achieved remission (DAPSA≤4), low disease activity (LDA) (5≥DAPSA≤14), minimal disease activity (MDA) (5/7) or very low disease activity (VLDA) (7/7) at least 1 time were calculated. Analysis were performed into three groups depends on type of therapy: 1st group (19 patients) – MTX-monotherapy; 2nd group (11 patients) – combination MTX with bDMARDs; 3rd group – 25 patients who stopped taken bDMARD by the end of the follow-up. Results. By 2 years of follow-up remission by DAPSA/LDA/MDA/VLDA was seen in 51.5%/16.2%/58.8%/42.65% of patients accordingly. In the 1st/2nd groups remission by DAPSA was noted in 68.4%/90% and MDA – in 81.8%/78.9% of patients accordingly. In the 3rd group remission by DAPSA/MDA maintained in 24%/32% of patients accordingly. Conclusion. The T2T strategy is optimal management approach in more than half of the ePsA patients despite of type of treatment within 2 years . The stopped of bDMARD caused a “lost” of remission/MDA in the most of patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|